Lymphangiectasia is a condition in which lymphatic vessels become abnormally dilated, allowing protein-rich lymph fluid to leak into surrounding tissues or body cavities. The intestinal form is the most widely studied, but lymphangiectasia can affect the lungs, skin, kidneys, and other organs. Because lymph carries proteins, fats, and immune cells, losing it disrupts nutrition, fluid balance, and the body’s ability to fight infections. The condition can be present from birth or develop later in life as a consequence of surgery, radiation, or other diseases that damage or obstruct lymphatic drainage.
What Happens Inside the Lymphatic System
The lymphatic system runs alongside blood vessels, collecting fluid, dietary fats, and immune cells and returning them to the bloodstream. In the gut, tiny lymphatic channels called lacteals sit inside each intestinal villus and absorb fat from digested food. When these channels become blocked or abnormally widened, pressure builds and the vessel walls stretch. Eventually they can rupture, spilling their contents into the intestinal lumen. The lost fluid, called chyle, is rich in albumin, immunoglobulins, and lymphocytes, so the body steadily loses critical proteins and immune cells through the digestive tract.
This leakage is what makes intestinal lymphangiectasia a “protein-losing enteropathy,” a term that simply means proteins are being shed through the gut wall faster than the body can replace them.1PubMed Central. Intestinal lymphangiectasia: Understanding the bigger picture The result is a cascade of problems: blood albumin drops, fluid shifts into tissues as edema, and immunoglobulin levels fall, weakening the immune system.
Primary Versus Secondary Forms
The distinction between primary and secondary lymphangiectasia matters because it shapes both the outlook and the treatment plan. Primary intestinal lymphangiectasia, sometimes called Waldmann’s disease after the physician who described it in the 1960s, is a developmental abnormality of the lymphatic vessels themselves. It typically shows up in childhood, often before age three, though some cases are not caught until adulthood. In congenital forms, the lymphatic channels simply never formed correctly or failed to undergo the normal regression that happens during fetal development.
Secondary lymphangiectasia develops when something else obstructs or damages previously normal lymphatic vessels. Heart failure that raises pressure in the veins draining the thoracic duct, inflammatory bowel disease, abdominal tumors, infections like tuberculosis, or complications from surgery and radiation can all block lymph flow and cause the vessels downstream to dilate. In secondary cases, treating the underlying cause can sometimes resolve the lymphangiectasia entirely, which is rarely possible in the primary form.
Symptoms That Bring People to a Doctor
The hallmark symptom of intestinal lymphangiectasia is swelling, usually in both legs but sometimes in the arms, face, or genitals. The edema is caused by low albumin in the blood: without enough albumin to hold fluid inside blood vessels, it seeps into surrounding tissues. People often notice that their legs feel heavy or that socks leave deep impressions on the skin.
Beyond edema, the chronic loss of lymph into the gut can cause:
- Diarrhea: often fatty and foul-smelling because fat absorption is impaired when lacteals are damaged.
- Fatigue and weakness: driven by malnutrition and low protein stores.
- Frequent infections: a direct consequence of losing immunoglobulins and lymphocytes.
- Growth failure in children: chronic nutrient and protein loss stunts normal development.
- Abdominal bloating or fluid: some patients develop ascites as fluid accumulates in the abdominal cavity.
These symptoms can wax and wane. Some people have long stretches with manageable swelling, then flare after a high-fat meal or an infection. The unpredictability is one of the most frustrating aspects for patients living with the condition.
How It Affects the Immune System
A study of 18 patients with intestinal lymphangiectasia found that levels of IgG, IgA, and IgM were all sharply reduced, not because the body stopped making them but because they were being lost through the gut far faster than normal. The fraction of the body’s IgG pool broken down each day was about five times the normal rate, and for IgM the rate was roughly four times normal.2Journal of Clinical Investigation. Intestinal Lymphangiectasia: a Protein-Losing Enteropathy with Hypogammaglobulinemia, Lymphocytopenia and Impaired Homograft Rejection The body tries to compensate by ramping up production, but it cannot keep pace.
The immune damage goes beyond antibodies. Research has shown that lymphangiectasia patients lose a disproportionate number of naive T cells, the type that have not yet encountered an infection and are essential for mounting responses to new threats. The pool of these cells in peripheral blood was strikingly reduced, while memory T cells, which recirculate differently and are less concentrated in lymph, were relatively spared.3PubMed. Intestinal lymphangiectasia, a disease characterized by selective loss of naive CD45RA+ lymphocytes into the gastrointestinal tract This selective depletion helps explain why patients struggle with new infections and show weakened skin-test reactions, even though they may handle familiar pathogens reasonably well.
Diagnosis and What Endoscopy Reveals
Blood tests showing low albumin, low lymphocyte counts, and low immunoglobulins raise suspicion, but the definitive diagnosis comes from seeing the dilated lymphatics directly. Upper endoscopy is the standard first step. During the procedure, the lining of the duodenum and jejunum often shows characteristic white spots, swollen villi with whitish tips, or a chyle-like coating over the mucosa.4PubMed. Endoscopic and histopathological study on primary and secondary intestinal lymphangiectasia These scattered white spots correspond to markedly dilated lymphatics inside the villi, visible even when the patient has been fasting.
A large study classifying endoscopic appearances in 123 patients with primary intestinal lymphangiectasia identified four distinct types: nodular, granular, vesicular, and edematous. The nodular and granular types involved all four layers of the small-intestinal wall, while the vesicular and edematous types mainly involved the inner mucosal and submucosal layers.5PubMed Central. Endoscopic classification and pathological features of primary intestinal lymphangiectasia This matters clinically because deeper involvement tends to be harder to treat and less responsive to dietary management alone.
Biopsies taken during endoscopy confirm the diagnosis histologically by showing dilated lymphatic channels in the mucosa and submucosa. But endoscopy only sees the surface. For understanding the full anatomy of the lymphatic leak, newer imaging techniques have become increasingly valuable.
Advanced Imaging With MR Lymphangiography
Dynamic contrast-enhanced magnetic resonance lymphangiography, or DCMRL, has changed how clinicians map lymphatic problems. By injecting contrast material and watching it move through the lymphatic system in real time, DCMRL can pinpoint exactly where lymph is leaking and whether the central lymphatic anatomy, including the thoracic duct and cisterna chyli, is intact.6PubMed. Dynamic contrast-enhanced magnetic resonance lymphangiography
In a study of patients with protein-losing enteropathy, intrahepatic injection of contrast detected a duodenal leak in about 71% of cases, and intranodal injection detected it in about 83%. Regardless of the underlying cause, the lymphatic leak was consistently localized to the duodenum.7PubMed Central. Dynamic contrast magnetic resonance lymphangiography localizes lymphatic leak to the duodenum in protein-losing enteropathy Knowing the precise location of the leak is not just an academic exercise; it is what allows interventional radiologists to plan targeted treatment. DCMRL has also been used as a preprocedural planning tool for embolization of lymphatic malformations complicated by chylous effusions.8PubMed Central. A Case of Embolization of a Lymphatic Malformation Complicated by Chylothorax, Chylopericardium, and Interstitial Lung Disease in a 6-Year-Old Pediatric Patient
Dietary Treatment and Why Fat Matters
A low-fat diet supplemented with medium-chain triglycerides (MCTs) is the first-line treatment and has been since the 1960s. The logic is straightforward: dietary long-chain fats are absorbed through intestinal lacteals, so eating fat engorges the already-compromised lymphatic vessels and promotes rupture. Removing fat from the diet reduces chyle flow through those vessels and slows the leak.9PubMed Central. Primary intestinal lymphangiectasia (Waldmann’s disease) MCTs, by contrast, are absorbed directly into the portal blood supply and bypass the lymphatics entirely, so they provide calories and essential fatty acids without contributing to lymphatic congestion.
In practice, adherence is demanding. Patients must keep dietary fat extremely low, often below 20 to 30 grams per day, and rely on MCT oil or MCT-enriched formulas to meet energy needs. Children face particular challenges because growth requires substantial calories, and a severely fat-restricted diet can become monotonous and socially isolating. Still, for many patients, dietary modification alone is enough to raise albumin levels and control edema. When it is not, clinicians escalate to pharmacological options.
Drug Therapy and Emerging Options
Octreotide, a synthetic hormone that reduces the flow of lymph and gut secretions, has been used in cases that do not respond to diet alone. Results have been mixed. A review of published case reports found that octreotide helped patients whose lymphangiectasia was confined to the intestine, but patients with extensive lymphatic involvement beyond the gut often failed to improve. Even among responders, symptoms tended to return when the drug was stopped.10PubMed Central. Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature
Sirolimus has emerged as a more promising option, particularly for patients with widespread lymphatic abnormalities. It works by targeting a signaling pathway involved in lymphatic vessel growth and proliferation, suppressing abnormal lymphatic sprouting and encouraging cell death in malformed vessels. In the same pediatric series, sirolimus produced clinical improvement in all four patients who received it, including two with extensive disease who had already failed octreotide. The two patients with disease limited to the intestine improved within three to four months, while those with extensive disease responded even faster, within about a month.11PubMed Central. Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature
A separate adult case series from a tertiary hospital painted a more nuanced picture. Among ten patients who received sirolimus, six showed sustained improvement lasting one to four years and remained on maintenance treatment, while three experienced limited benefit and discontinued. For octreotide, three of seven patients saw no effect at all.12PubMed Central. Experience of primary intestinal lymphangiectasia in adults: Twelve case series from a tertiary referral hospital The takeaway from these small series is that no single drug works reliably for everyone, and clinicians often need to try more than one approach before finding what helps a given patient.
Surgical and Interventional Approaches
When the lymphatic abnormality is localized to a short segment of intestine, surgical resection, simply cutting out the affected section, can be curative. This option is reserved for patients who have clearly focal disease and have not responded to dietary or medical therapy.13PubMed Central. The Update of Treatment for Primary Intestinal Lymphangiectasia The challenge is that many patients have diffuse involvement across a long stretch of the small bowel, making resection impractical without causing short-bowel syndrome.
Lymphatic embolization is a newer interventional technique gaining traction. Using DCMRL to identify the specific leaking lymphatic channel, interventional radiologists thread a catheter to the site and seal it with medical-grade glue. In one pediatric case, a child whose albumin had fallen to 1.5 g/dL saw it rise to 5.0 g/dL after two embolization sessions, a dramatic improvement.14PubMed Central. Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia The authors suggested embolization could be considered a first-line option for focal lesions, a notably bold recommendation for what is still a relatively new procedure. While traditionally performed in adults, the technique has been successfully adapted for children as well.
A Genetic Angle
Most cases of primary intestinal lymphangiectasia appear sporadically, with no clear family pattern. But genetic testing in some pediatric cohorts has turned up identifiable mutations. In a study of Chinese children with early-onset protein-losing enteropathy, genetic sequencing found mutations in CCBE1 and DGAT1 among patients with confirmed lymphangiectasia on endoscopy.15PubMed. Phenotype and Genotype of a Cohort of Chinese Children with Early-Onset Protein-Losing Enteropathy CCBE1 is involved in lymphatic vessel development, and defects in it have been linked to a broader category of lymphatic malformations. DGAT1 plays a role in fat metabolism, and its loss disrupts lipid handling in the gut in ways that mimic or worsen lymphangiectasia.
These findings do not mean every case of primary lymphangiectasia has a single-gene cause. In most patients, genetic testing comes back unremarkable, and the condition is likely the result of complex developmental events that are not well understood. But identifying a genetic basis in a subset of patients could eventually lead to more targeted therapies and better genetic counseling for affected families.
Lymphangiectasia Beyond the Gut
While the intestinal form gets most of the clinical attention, lymphangiectasia can appear in several other organ systems, each with its own set of problems.
Pulmonary Lymphangiectasia
Congenital pulmonary lymphangiectasia involves dilated lymphatic channels in the lung tissue, around blood vessels, airways, and beneath the pleural surface. It typically presents at birth with severe respiratory distress, rapid breathing, and cyanosis. The mortality rate is very high, with many infants dying within hours of birth.16PubMed Central. Congenital pulmonary lymphangiectasia The leading theory is that fetal lung lymphatics fail to undergo their normal involution around 20 weeks of gestation. Secondary pulmonary lymphangiectasia can also develop in children with congenital heart defects that raise venous pressure in the chest. Among infants who survive the initial crisis, outcomes have improved with modern neonatal intensive care, but long-term respiratory issues are common.
Cutaneous Lymphangiectasia
Lymphangiectasia of the skin most often appears as an acquired condition, developing in areas where lymphatic drainage has been damaged by surgery or radiation. After mastectomy and radiation therapy for breast cancer, for example, some women develop clusters of small, clear or blood-tinged vesicles on the chest wall, sometimes years after treatment.17PubMed Central. Acquired lymphangiectasis following surgery and radiotherapy of breast cancer These vesicles represent dilated superficial lymphatics and can leak fluid, become infected, or cause cosmetic distress. The condition is also called lymphangioma circumscriptum in some older literature, and cases have been documented appearing as late as eight years after the initial cancer treatment.18PubMed. Lymphangioma circumscriptum following mastectomy and radiation therapy
Renal Lymphangiectasia
Renal lymphangiectasia involves dilated lymphatic channels in or around the kidneys. It tends to be congenital and is most often diagnosed in children, though it can be found incidentally on imaging done for other reasons.19PubMed. Imaging of Perirenal and Intrarenal Lymphatic Vessels: Anatomy-based Approach On ultrasound and CT, it appears as multiple cystic spaces in the renal hilum or perirenal area, and imaging sometimes reveals associated dilation of deeper lymphatic structures like the cisterna chyli and thoracic duct.20PubMed Central. Bilateral renal lymphangiectasia: radiological findings by ultrasound, computed tomography, and magnetic resonance imaging Many cases are asymptomatic and discovered incidentally, but when the dilated lymphatics compress kidney tissue, patients can develop flank pain and abnormal kidney function tests. Management is usually conservative and involves monitoring with periodic imaging.
Lymphangiectasia in Dogs
If you have come across lymphangiectasia while researching a sick pet, you are not alone. The condition is well recognized in veterinary medicine, particularly in certain dog breeds like Yorkshire Terriers, Soft-Coated Wheaten Terriers, and Maltese. The basic pathology is similar to the human version: dilated intestinal lymphatics, protein loss, and low albumin.
There is an interesting divergence in treatment philosophy between human and veterinary medicine. In people, dietary fat restriction and MCT supplementation are the mainstay, and immunosuppressive drugs are rarely used because there is no recognized immune-driven component. In dogs, corticosteroids and other immunosuppressive medications are much more commonly part of the treatment plan, reflecting the frequent overlap between lymphangiectasia and inflammatory bowel disease in canine patients.21PubMed Central. Pathophysiology, Diagnosis, and Management of Canine Intestinal Lymphangiectasia: A Comparative Review
Dietary fat restriction works in dogs as it does in people. A study of 24 dogs with intestinal lymphangiectasia found that about 79% responded well to dietary fat restriction, with albumin levels rising significantly within one to two months and corticosteroid doses being reduced or stopped.22PubMed Central. The Clinical Efficacy of Dietary Fat Restriction in Treatment of Dogs with Intestinal Lymphangiectasia Dogs fed an ultra-low-fat diet without any added supplemental fat had higher albumin levels than those on an ultra-low-fat diet with a small amount of added fat, suggesting that in canine patients, the stricter the fat restriction, the better the outcome.